Measuring quality of life in macular disease: what use are utilities?
Jan Mitchell and Clare Bradley
Health Psychology Research, Department of Psychology, Royal Holloway University of London, Egham, Surrey, TW20 0EX, UK.

Table 1. Correlations between outcome measures

<table>
<thead>
<tr>
<th></th>
<th>General health</th>
<th>Health TTO</th>
<th>Vision TTO</th>
<th>MD-specific QoL</th>
<th>Generic QoL</th>
<th>Registration status</th>
</tr>
</thead>
<tbody>
<tr>
<td>MacDQoL AWI</td>
<td>0.089</td>
<td>0.065</td>
<td>0.098</td>
<td>0.639*</td>
<td>0.298*</td>
<td>0.444*</td>
</tr>
<tr>
<td>Registration status</td>
<td>0.18</td>
<td>0.099</td>
<td>0.033</td>
<td>0.426*</td>
<td>0.004</td>
<td></td>
</tr>
<tr>
<td>Generic QoL</td>
<td>0.561*</td>
<td>0.15</td>
<td>0.1</td>
<td>0.069</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MD-specific QoL</td>
<td>-0.105</td>
<td>0.020</td>
<td>0.117</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vision TTO</td>
<td>0.054</td>
<td>0.731*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health TTO</td>
<td>0.172</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*significant at p &lt; 0.01</td>
</tr>
</tbody>
</table>

Conclusions

Lower TTO completion rates suggest reduced face validity and less acceptability of TTO questions.
TTO questions less sensitive to subgroup differences than MacDQoL (AWI) and MD-specific overview item.
Frequency and distribution of U = 1 and comments about TTO questions indicate that people may not be willing to co-operate with TTO utilities methodology and, when they are, their responses do not provide a measure of QoL.

References

1 Arnold JJ and Sarks SH. Age-related macular degeneration. BMJ 2000; 321: 741-744
2 Mitchell J and Bradley C. Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Quality of Life Research; in press
4 Dolan P and Roberts J. To what extent can we explain time trade off values from other information about respondents? Social Science and Medicine 2002; 54, 319-925

Acknowledgements

Our thanks go to members of the MD Society who took part in the research and to Alcon Pharmaceuticals, who funded the work.

References

1 Arnold JJ and Sarks SH. Age-related macular degeneration. BMJ 2000; 321: 741-744
2 Mitchell J and Bradley C. Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Quality of Life Research; in press
4 Dolan P and Roberts J. To what extent can we explain time trade off values from other information about respondents? Social Science and Medicine 2002; 54, 319-925

Acknowledgements

Our thanks go to members of the MD Society who took part in the research and to Alcon Pharmaceuticals, who funded the work.

Enquiries

Corresponding author:
Jan Mitchell PhD
Professor of Health Psychology
Royal Holloway, University of London
Egham, Surrey, TW20 0EX, UK.
E-mail: j.mitchell@rhul.ac.uk

Access to publications:
Clare Bradley PhD
Professor of Health Psychology
Royal Holloway, University of London
Egham, Surrey, TW20 0EX, UK.
E-mail: c.bradley@rhul.ac.uk

Measuring quality of life in macular disease: what use are utilities?
Jan Mitchell and Clare Bradley
Health Psychology Research, Department of Psychology, Royal Holloway University of London, Egham, Surrey, TW20 0EX, UK.

Table 1. Correlations between outcome measures

<table>
<thead>
<tr>
<th></th>
<th>General health</th>
<th>Health TTO</th>
<th>Vision TTO</th>
<th>MD-specific QoL</th>
<th>Generic QoL</th>
<th>Registration status</th>
</tr>
</thead>
<tbody>
<tr>
<td>MacDQoL AWI</td>
<td>0.089</td>
<td>0.065</td>
<td>0.098</td>
<td>0.639*</td>
<td>0.298*</td>
<td>0.444*</td>
</tr>
<tr>
<td>Registration status</td>
<td>0.18</td>
<td>0.099</td>
<td>0.033</td>
<td>0.426*</td>
<td>0.004</td>
<td></td>
</tr>
<tr>
<td>Generic QoL</td>
<td>0.561*</td>
<td>0.15</td>
<td>0.1</td>
<td>0.069</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MD-specific QoL</td>
<td>-0.105</td>
<td>0.020</td>
<td>0.117</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vision TTO</td>
<td>0.054</td>
<td>0.731*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health TTO</td>
<td>0.172</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*significant at p &lt; 0.01</td>
</tr>
</tbody>
</table>

Conclusions

Lower TTO completion rates suggest reduced face validity and less acceptability of TTO questions.
TTO questions less sensitive to subgroup differences than MacDQoL (AWI) and MD-specific overview item.
Frequency and distribution of U = 1 and comments about TTO questions indicate that people may not be willing to co-operate with TTO utilities methodology and, when they are, their responses do not provide a measure of QoL.

References

1 Arnold JJ and Sarks SH. Age-related macular degeneration. BMJ 2000; 321: 741-744
2 Mitchell J and Bradley C. Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Quality of Life Research; in press
4 Dolan P and Roberts J. To what extent can we explain time trade off values from other information about respondents? Social Science and Medicine 2002; 54, 319-925

Acknowledgements

Our thanks go to members of the MD Society who took part in the research and to Alcon Pharmaceuticals, who funded the work.

Enquiries

Corresponding author:
Jan Mitchell PhD
Professor of Health Psychology
Royal Holloway, University of London
Egham, Surrey, TW20 0EX, UK.
E-mail: j.mitchell@rhul.ac.uk

Access to publications:
Clare Bradley PhD
Professor of Health Psychology
Royal Holloway, University of London
Egham, Surrey, TW20 0EX, UK.
E-mail: c.bradley@rhul.ac.uk